Wo2015173181 risdiplam patent?

Short answer: Yes. WO2015173181 is the WIPO international publication for risdiplam (RG7916), the oral SMN2 splicing modifier developed for spinal muscular atrophy (SMA).

What it covers (at a high level)
- Discloses risdiplam and related compounds and their chemical families.
- Describes methods of using these compounds to treat SMA by modulating SMN2 splicing to increase SMN protein.
- Provides synthesis examples, pharmaceutical compositions/formulations, and dosing concepts.
- Includes contemplated medical uses beyond SMA in some embodiments.

Who owns the family (typical for this kind of filing)
- The publication is part of a patent family associated with Roche (and in collaborations related to SMA programs). There are US/EU/other national phase counterparts that cover similar claims.

If you want more detail
- I can pull out the key claim scope, list representative compounds/structures, and summarize the US/EU equivalents and their status in your jurisdiction.
- I can also help you check current patent status (granted/expired, term dates) and freedom-to-operate considerations for a specific country.

Would you like a claim-by-claim summary, or a patent-family landscape (assignees, grant status, expiries) for risdiplam in a particular country?